<DOC>
	<DOCNO>NCT02987699</DOCNO>
	<brief_summary>The purpose phase II study determine recommend dose , well safety efficacy combination oxaliplatin , leucovorin 5-Fu introduce hepatic arterial infusion chemotherapy ( HAIC ) patient advance hepatocellular carcinoma ( HCC ) .</brief_summary>
	<brief_title>Phase II Study HAIC Using Cisplatin , Leucovorin 5-Fluorouracil</brief_title>
	<detailed_description>The result preliminary pilot study suggest combination oxaliplatin , leucovorin 5-Fu introduce hepatic arterial infusion chemotherapy ( HAIC ) may improve survival advanced stage HCC . Thus , investigator carry prospective randomize control study determine recommend dose well safety efficacy .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>The diagnosis HCC base diagnostic criterion HCC use European Association Study Liver ( EASL ) Patients must least one tumor lesion accurately measure accord EASL criterion . diagnosed major main portal vein invasion ( Vp3 Vp4 ) KPS≥70； previous treatment No Cirrhosis cirrhotic status ChildPugh class A Not amendable surgical resection , local ablative therapy cure treatment . The following laboratory parameter : Platelet count ≥ 75,000/µL Hemoglobin ≥ 8.5 g/dL Total bilirubin ≤ 30mmol/L Serum albumin ≥ 30 g/L ASL AST ≤ 5 x upper limit normal Serum creatinine ≤ 1.5 x upper limit normal INR ≤ 1.5 PT/APTT within normal limit Absolute neutrophil count ( ANC ) &gt; 1,500/mm3 Ability understand protocol agree sign write informed consent document Evidence hepatic decompensation include ascites , gastrointestinal bleeding hepatic encephalopathy Known history HIV History organ allograft Known suspect allergy investigational agent agent give association trial . Cardiac ventricular arrhythmia require antiarrhythmic therapy Evidence bleeding diathesis . Patients clinically significant gastrointestinal bleeding within 30 day prior study entry . Any hemorrhage/bleeding event &gt; CTCAE Grade 3 within 4 week first dose study drug Serious nonhealing wound , ulcer , bone fracture Known central nervous system tumor include metastatic brain disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Hepatic arterial infusion chemotherapy</keyword>
	<keyword>optimal dose</keyword>
</DOC>